Efficacy and Safety of Biphasic Insulin Aspart 30/70 in Type 2 Diabetes Suboptimally Controlled on Oral Antidiabetic Therapy in Korea: A Multicenter, Open-Label, Single-Arm Study.
10.4093/dmj.2013.37.2.117
- Author:
Kee Ho SONG
1
;
Jung Min KIM
;
Jung Hyun NOH
;
Yongsoo PARK
;
Hyun Shik SON
;
Kyong Wan MIN
;
Kyung Soo KO
Author Information
1. Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea.
- Publication Type:Multicenter Study ; Original Article
- Keywords:
Diabetes mellitus, type 2;
Glycemic control;
Insulin aspart, insulin aspart protamine drug combination 30:70
- MeSH:
Biphasic Insulins;
Blood Glucose;
Diabetes Mellitus, Type 2;
Hemoglobin A, Glycosylated;
Humans;
Hypoglycemia;
Hypoglycemic Agents;
Insulin Aspart;
Insulin, Isophane;
Korea;
Quality of Life
- From:Diabetes & Metabolism Journal
2013;37(2):117-124
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: The purpose of this study was to evaluate change in glycosylated hemoglobin (HbA1c), side effects, and quality of life (QOL) after a 16-week treatment period with Biphasic insulin aspart 30/70 (BIasp30) in patients with type 2 diabetes mellitus (T2DM) who had been suboptimally controlled with oral antidiabetic drugs (OADs). METHODS: The study consisted of a 4-week titration period when concurrent OAD(s) were replaced with BIasp30 and followed by a 12-week maintenance period. All patients completed the Diabetes Treatment Satisfaction Questionnaire at the beginning and the end of the trial. Hypoglycemic episodes were recorded by the patient throughout the trial. RESULTS: Sixty patients were included, of whom 55 patients (92%) completed the full 16-week treatment period. Seven-point blood glucose was significantly improved as compared with the baseline, except for the postlunch blood glucose level. HbA1c at the end of period was significantly improved from 9.2% to 8.2% (P<0.001). Eleven percent (n=6) of patients achieved HbA1c values < or =6.5% and 22% (n=12) of patients achieved <7.0%. There were 3.4 episodes/patients-year of minor hypoglycemia and 0.05 episodes/patients-year of major hypoglycemia. QOL showed significant changes only in the acceptability of high blood glucose category (P=0.003). CONCLUSION: Treatment with once or twice daily BIasp30 may be an option for the patients with T2DM suboptimally controlled with OADs in Korea. However, considering the low number of patients achieving the HbA1c target and the high postlunch blood glucose levels, additional management with another modality may be required for optimal control.
